Advance in Nanoparticles for Tumor Targeting
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biological and Bio- Materials".
Deadline for manuscript submissions: closed (20 May 2024) | Viewed by 6013
Special Issue Editor
Interests: nanotechnology; cancer therapy; targeted therapy; protein-based nanoparticles; drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A growing number of nanoparticle delivery systems have been developed and approved for clinical use in cancer diagnosis and therapy. The biotechnological advances combining structure, sizes, natures, and the incorporation of active targeting (using molecules such as ligands, antibodies, peptides, and RNA aptamers), together with their functionalization with multiple classes of chemotherapeutics for delivery into tumor cells, have improved the efficacy and reduced toxicity over conventional cancer treatments. The major challenges are now how different combinations of nanoparticle delivery systems can be rationally designed to maximize the efficacy and safety. During cancer progression, tumors become highly heterogeneous, containing different cellular populations such as cancer stem cells, stroma cells, and the tumor microenvironment (TME), which are characterized by distinct molecular features and a different responsivity to therapies. This heterogeneity is the main cause that limits the therapeutic value of many drugs, and it is further associated with a fatal disease. These new molecular and cellular targets could be a key factor in nanopharmaceutical development, allowing for the design of multi-targeting approaches given efficient and precise therapies to increase the clinical impact of cancer treatments.
Dr. Maria Virtudes Céspedes
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- chemotherapeutic drug-based nanoparticles
- targeted nanoparticle-based therapy
- nanoparticle technology platforms
- nanocarriers
- drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.